|
|
||||||||
J Biol Chem, Vol. 274, Issue 40, 28632-28636, October 1, 1999
From the Mutations in the cytoplasmic domain of the
insulin receptor that block the ability of the receptor to stimulate
glucose uptake do not block the receptor's ability to inhibit
apoptosis (Boehm, J. E., Chaika, O. V., and Lewis, R. E. (1998) J. Biol. Chem. 273, 7169-7176). To
characterize this survival pathway we used a chimeric receptor
(CSF1R/IR) consisting of the ligand-binding domain of the
colony-stimulating factor-1 receptor spliced to the cytoplasmic domain
of the insulin receptor and a mutated version of the chimeric receptor
containing a 12-amino acid deletion of the juxtamembrane domain
(CSF1R/IR The cellular receptor for insulin controls diverse intracellular
pathways that regulate metabolism, growth, and development. One
conventional approach for identifying the molecular components that
constitute these different pathways has been the selective mutagenesis
of the receptor's cytoplasmic domain in an effort to discretely
dissociate one biological action of insulin from another (1-7). These
observations have led to the suggestion that different regions of the
insulin receptor cytoplasmic domain play distinct roles in modulating
the biological effects of insulin.
The insulin and IGF I1
receptors are potent inhibitors of apoptosis (6, 8, 9). Recent studies
with a CSF1R/IR suggest that the insulin receptor cytoplasmic domain
activates intracellular signaling pathways that are independent of its
ability to phosphorylate IRS proteins and Shc (5, 6). The mutated
CSF1R/IR Previous studies of anti-apoptotic signaling by growth factor receptors
have identified PI 3-kinase and the serine/threonine kinase Akt as part
of the mechanism that promotes cell survival (10-13). The insulin and
IGF I receptors activate PI 3-kinase and, subsequently, Akt through
their ability to phosphorylate IRS proteins at sites that facilitate
interaction of these receptor substrates with the noncatalytic subunit
of PI 3-kinase, p85 (14-16). These observations suggested that
alternative pathways could contribute to the insulin receptor's
anti-apoptotic activity.
To identify additional mediators of anti-apoptotic signaling activated
by the insulin receptor cytoplasmic domain, other biological effects of
the CSF1R/IR Plasmids and Constructs--
cDNAs encoding Myc-tagged
RacV12, RacN17, Cdc42V12,
Cdc42N17, Ha-RasD12, and Ha-RasN17
were gifts from A. Hall (London). Each cDNA was cloned into the EcoRI site of the retroviral vector pSR Cell Lines--
Rat1 mycER fibroblasts (18) (G. Evan, London)
were transfected with the CSF1R/IR or the CSF1R/IR Analysis of Akt--
Cells expressing the CSF1R/IR or the
CSF1R/IR Microinjection and Immunofluorescence--
Rat1mycER (5 × 104) cells expressing the CSF1R/IR or the CSF1R/IR Quantification of Apoptosis--
Apoptosis in cells stably
expressing activated or dominant-negative forms of Ras, Rac 1, or Cdc42
was determined by time-lapse video microscopy (8) and by determining
the number of apoptotic cells on a specific grid at 0, 10, and 20 h posttreatment. Fields of at least 300 cells were used to quantify apoptosis.
Apoptosis in cells microinjected with RacN17 was determined
by co-injection with 20 ng/µl pEFGFP. Cells were treated with 100 nM tamoxifen, 10 nM CSF-1, or 1 µM insulin as indicated, and cells expressing GFP were
observed every 2 h for a total of 20 h. The amount of
apoptosis among injected cells was quantified. Cell death caused by
microinjection was determined by the injection of pEFGFP alone and
subtracted from the amount of death induced by each experimental
condition. Microinjected cells expressing GFP were evaluated within the
microscopic field for each condition. Each condition was repeated at
least five times.
Previous studies have shown that mutations in the CSF1R/IR can
dissociate its ability to phosphorylate important intracellular substrates from certain receptor-stimulated biological effects (5, 6).
A 12-amino acid deletion ( Insulin and insulin-like growth factors rapidly induce membrane
ruffling (lamellipodia) in cells (21, 22). To investigate the effect of
the We observed previously that the
Rac-dependent Anti-apoptotic Signaling by the Insulin
Receptor Cytoplasmic Domain*
§,
, and
¶
**
Eppley Institute for Research in Cancer and
Allied Diseases, ¶ Department of Biochemistry and Molecular
Biology, and
Department of Pathology and Microbiology,
University of Nebraska Medical Center, Omaha, Nebraska 68198-6805
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
960). In addition to the inhibition of apoptosis, activation of either the CSF1R/IR or the CSF1R/IR
960 rapidly induced
membrane ruffling in Rat1 fibroblasts. The small GTPase Rac mediates
membrane ruffling. Activated and dominant-inhibitory mutants of Rac and
other small GTPases were expressed in Rat1 fibroblasts to examine a
potential link between the intracellular pathways that induce membrane
ruffling and promote cell survival. The anti-apoptotic action of the
CSF1R/IR
960 was reversed by dominant-inhibitory RacN17,
but not by RasN17 or Cdc42N17. Activated
RacV12, but not RasD12 or Cdc42V12,
promoted cell survival in the absence of insulin. These data implicate
Rac as a mediator of an unique anti-apoptotic signaling pathway
activated by the insulin receptor cytoplasmic domain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
960 lacks the ability to phosphorylate the receptor
substrates IRS-1 and Shc. Coincident with the loss of receptor
substrate phosphorylation, the
960 deletion also blocks the
activation of ERK MAP kinases, the activation of PI 3-kinase associated
with IRS-1, and the stimulation of glucose transport. However, the
960 deletion does not prevent the receptor from inhibiting apoptosis
(6).
960 were investigated. We observed that the
CSF1R/IR
960 rapidly induced membrane ruffling in a manner dependent
on the small GTPase Rac. A contribution of Rac to anti-apoptotic signaling by the chimeric receptor was indicated by the observation that dominant-negative RacN17 blocked survival signals from
the CSF1R/IR
960. Furthermore, activated RacV12, but not
activated RasD12 or Cdc42V12, was sufficient to
promote survival in the absence of growth factor stimulation. These
results implicate Rac as a mediator of an additional anti-apoptotic
signaling pathway activated by the insulin receptor cytoplasmic domain
in a manner independent of IRS phosphorylation.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
. Recombinant
retroviruses were made by transfection into a packaging cell line (17).
cDNAs encoding RacV12 and RacN17 containing
a T7 epitope tag were gifts of D. Bar-Sagi (Stony Brook, NY). The
CSF1R/IR and CSF1R/IR
960 were constructed previously (5).
960 with
LipofectAMINE (Life Technologies, Inc.). Stable lines expressing each
chimeric receptor were isolated as described previously (5) by
selection with G418 followed by fluorescence-activated cell sorting
using an antibody to the ligand binding domain of the human CSF-1
receptor. For the expression of activated and dominant-negative forms
of Rac, Ras, and Cdc42, Rat1 mycER cells were infected at a
multiplicity of infection of at least 5 with ecotropic retroviruses
encoding each Myc-tagged cDNA and selected with G418 (400 µg/ml).
960 (5 × 105/35-mm dish) were treated with
or without 10 nM CSF-1 or 100 nM insulin for 10 min, lysed, and the phosphorylation state of Akt was determined by
Western blot with PhosphoPlus Akt (Ser473) antibodies (New
England Biolabs). Akt kinase activity was determined as described
previously (19) by the phosphorylation of histone H2B in
immunoprecipitates of Akt from treated and untreated cells.
960
were plated onto gridded glass coverslips (Bellco), incubated in
serum-free Dulbecco's modified Eagle's medium for 24 h, and injected as described previously for REF-52 fibroblasts (20) with 50 ng/µl pCGT T7-tagged RacV12 or RacN17 using
an Eppendorf automated microinjection system. The expression of
RacV12 and RacN17 were detected with mouse
anti-T7 antibodies (1:700, Novagen) and FITC-conjugated goat anti-mouse
antibodies (1:100, Southern Biotechnology Associates) in cells fixed
with 2.5% paraformaldehyde and permeablized with 0.1% Triton X-100.
Membrane ruffles were detected in fixed and permeablized cells with
0.01 µg/ml TRITC-phalloidin.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
960) blocks the ability of the CSF1R/IR to
phosphorylate IRS-1 and Shc, activate the MAP kinases ERK1 and ERK2,
activate PI 3-kinase associated with IRS-1, and stimulate glucose
transport (5, 6). Despite the uncoupling of these intracellular
effectors from the receptor, the CSF1R/IR
960 still retains its
ability to stimulate adipocyte differentiation (5) and protect cells
against apoptosis (6). However, inhibition of apoptosis and induction
of differentiation are assayed over much longer periods of time (hours
to days) than the amount of time (minutes) required to detect
biological events that are inhibited by the
960 mutation. This fact
prevented us from excluding the possibility that small amounts of IRS
or Shc phosphorylation could result from prolonged activation of the
CSF1R/IR
960 to inhibit apoptosis or stimulate differentiation. We,
therefore, looked for biological effects of insulin that could be
mimicked by activation of the CSF1R/IR and occurred over the same rapid
time course as the phosphorylation of insulin receptor substrates and
the stimulation of glucose uptake.
960 deletion on the ability of the chimeric receptor to
stimulate membrane ruffling, Rat1mycER fibroblasts stably expressing
the CSF1R/IR, the CSF1R/IR
960, or transfected with the expression
vector alone were treated with or without 10 nM CSF-1 or
100 nM insulin for 2 min. The cells were fixed immediately,
and polymerized actin was detected with TRITC-labeled phalloidin.
Fluorescence microscopy revealed that CSF-1 and insulin rapidly induced
lamellipodia in cells expressing either the CSF1R/IR or CSF1R/IR
960
(Fig. 1). However, in control cells only
insulin was able to induce membrane ruffling (Fig. 1). The ability of the CSF1R/IR
960 to rapidly stimulate membrane ruffling suggested that the induction of this cytoskeletal rearrangement was not dependent
upon IRS and Shc phosphorylation. Lamellipodia formation is dependent
upon the activation of the small GTPase Rac (23). To investigate the
role of Rac in lamellipodia formation by the CSF1R/IR
960,
dominant-inhibitory RacN17 was microinjected into Rat1mycER
fibroblasts expressing the CSF1R/IR
960, and the cells were treated
with CSF-1. Expression of RacN17 blocked the ability of
CSF-1 to induce membrane ruffling in microinjected cells, but not in
adjacent, uninjected cells (data not shown).

View larger version (147K):
[in a new window]
Fig. 1.
Membrane ruffling in cells expressing the
CSF1R/IR or the CSF1R/IR
960. Rat1mycER
cells stably transfected with the expression vector alone, or
expressing the CSF1R/IR or the CSF1R/IR
960 were incubated in
serum-free media for 48 h, treated with or without 100 nM insulin or 10 nM CSF-1 for 2 min, and fixed
immediately with 2.5% paraformaldehyde. Actin microfilaments were
detected with TRITC-phalloidin. Lamellipodia are indicated by the
white arrows.
960 mutation blocks the ability of
the CSF1R/IR to stimulate PI 3-kinase activity associated with tyrosine
phosphorylated proteins, including IRS-1 (6). Phosphorylation of the 3'
position of PI is thought to be a key event in the activation of
guanine nucleotide exchange factors for Rac (24, 25). Binding of
PI(3,4,5)P3 to the pleckstrin homology domain of Akt is
also critical to the activation of the serine/threonine kinase
(26-29). To confirm that the CSF1R/IR
960 was not activating known
PI 3-kinase signaling pathways, the ability of cells expressing the
CSF1R/IR or the CSF1R/IR
960 to activate Akt was examined. Insulin
(100 nM) stimulated the phosphorylation of Akt in cells
expressing the CSF1R/IR or the CSF1R/IR
960, as determined by Western
blotting with an antibody specific for Akt phosphorylated on
Ser473. However, only cells expressing the intact CSF1R/IR
were able to stimulate phosphorylation in response to CSF-1 treatment
(Fig. 2A). The level of Akt
expressed in each treatment group was similar, suggesting that the
960 mutation was responsible for the inability of CSF-1 to stimulate
Akt phosphorylation in cells expressing the chimeric receptor (Fig.
2B). Similar results were obtained when the kinase activity
of Akt was analyzed. CSF-1 stimulated the kinase activity of Akt
immunoprecipitated from cells expressing the intact CSF1R/IR but not
from cells expressing the CSF1R/IR
960 (Fig. 2C). These
data indicate the activation of Akt by the insulin receptor kinase is
dependent upon IRS-associated PI 3-kinase activity but that the rapid,
Rac-dependent induction of lamellipodia by the
CSF1R/IR
960 is independent of the activation of PI 3-kinase. Alternatively, a second, distinct PI 3-kinase pathway may also be
stimulated independent of IRS proteins by the insulin receptor kinase
to activate Rac.

View larger version (37K):
[in a new window]
Fig. 2.
Phosphorylation and activation of Akt in
cells expressing the CSF1R/IR or
CSF1R/IR
960. Rat1mycER cells expressing
the CSF1R/IR or the CSF1R/IR
960 were left untreated or treated with
10 nM CSF-1 or 100 nM insulin for 10 min at
37 °C. A, activated Akt was immunoprecipitated from the
cell lysates using phospho-specific Akt antibodies, separated by
electrophoresis, and blotted to nitrocellulose. Activated Akt was
detected by probing the blots with the phospho-specific Akt antibodies.
B, the Akt expression in the samples from A was
determined by immunoprecipitation and probing a portion of the cell
lysate with antibodies to Akt. C, the activation of Akt was
determined by examining the phosphorylation of histone H2B by Akt
immunoprecipitated from cells expressing the CSF1R/IR or the
CSF1R/IR
960. Cells were treated with CSF-1 or insulin as indicated.
D, the Akt expression in the samples from C was
determined by immunoprecipitating and probing a portion of the cell
lysate with antibodies to Akt.
PI 3-kinase and Akt are known mediators of growth factor-stimulated
anti-apoptotic signaling pathways (10-13). CSF-1 inhibited apoptosis
(6) and stimulated Rac-dependent membrane ruffling (Fig.
1), but was unable to activate PI 3-kinase (6) or Akt (Fig. 2) in cells
expressing the CSF1R/IR
960. These observations raise the possibility
that Rac mediates anti-apoptotic signaling by the insulin receptor
cytoplasmic domain. To test the role of Rac in anti-apoptotic signaling
by insulin, constitutively active or dominant-inhibitory forms of small
GTPases were stably expressed in Rat1mycER fibroblasts and tested
for their ability to inhibit apoptosis. Rat1mycER cells alone or
expressing the different small GTPases were treated with 100 nM tamoxifen to induce apoptosis (18) and with or without 1 µM insulin for 20 h. Cells expressing RacV12 and treated with 100 nM tamoxifen showed
a significantly reduced level of apoptosis when compared with control
Rat1mycER cells treated with tamoxifen (Fig.
3A). Furthermore, insulin
treatment did not enhance the survival of tamoxifen-treated cells
expressing RacV12. The protective role of
RacV12 in tamoxifen-treated Rat1mycER fibroblasts was
further demonstrated by time-lapse video microscopy (Fig.
3B). In contrast, the expression of activated
Cdc42V12 showed no ability to protect cells from
tamoxifen-induced apoptosis and had no effect on insulin's
anti-apoptotic activity, suggesting that Cdc42 is not involved in an
insulin-mediated survival pathway (Fig. 3A). Activated
RasD12 also had no protective effect against
tamoxifen-induced apoptosis, but instead inhibited the anti-apoptotic
activities of insulin. The actions of activated RasD12 are
consistent with the observation that activated Ras has
pro-apoptotic activity in Rat1mycER cells through its stimulation
of ERK MAP kinases (13). These results suggest that Rac is distinct in its ability to promote cell survival in the presence of an apoptotic stimulus.
|
The expression of dominant-inhibitory Cdc42N17 or
RasN17 in Rat1mycER cells had no effect on
tamoxifen-induced apoptosis and did not alter insulin's ability to
inhibit tamoxifen-induced apoptosis (Figs. 3, C and
D). We were unable to create cell lines stably expressing
RacN17. As a second approach toward determining whether Rac
contributed to survival signaling, plasmids encoding
dominant-inhibitory RacN17 were microinjected into
Rat1mycER fibroblasts expressing the CSF1R/IR
960 (Fig.
4). Apoptosis in untreated cells was
11.5%, whereas tamoxifen treatment alone elevated the level of
apoptosis to 36.3%. Tamoxifen treatment in combination with insulin or
CSF-1 significantly reduced the amount of apoptosis to 18.9% and 20%, respectively. Untreated cells injected with an expression plasmid encoding RacN17 showed a level of apoptosis comparable with
untreated cells or cells treated with tamoxifen plus insulin or CSF-1.
Tamoxifen increased apoptosis in cells injected with plasmids encoding
RacN17 to the same extent as control injected cells treated
with tamoxifen, which demonstrated that dominant-inhibitory
RacN17 has no protective effect on the cells. However, the
anti-apoptotic effects of insulin and CSF-1 were lost in cells injected
with RacN17 (Fig. 4).
|
The data demonstrate that receptor signaling to Rac is independent of
the phosphorylation of IRS-1 and Shc, as a deletion in the
juxtamembrane domain prevented the chimeric CSF1R/IR (6) and the intact
insulin receptor (1, 30-32) from interacting with and phosphorylating
these important signaling intermediates. Ras (33), Cdc42, (34) and PI
3-kinase (35) are considered to be activators of Rac. However, CSF1R/IR
activation of Ras-regulated pathways is inhibited by the
960
mutation (6), and neither dominant-inhibitory RasN17 nor
Cdc42N17 blocked the ability of the CSF1R/IR
960 to
induce membrane ruffling (data not shown) or survival (Fig. 3). PI
3-kinase associated with IRS-1 is activated by the CSF1R/IR, but is not
activated by the CSF1R/IR
960 (6). These previous observations and
the data presented here suggest the existence of a novel intracellular signaling pathway used by the insulin receptor kinase to induce membrane ruffling and to transmit intracellular signals promoting cell survival.
The PI 3-kinase-dependent activation of Akt and the
subsequent phosphorylation of the pro-apoptotic protein Bad (12),
caspase 9 (36), and the forkhead transcription factor FKHRL1 (37) have
been identified previously as elements of a growth factor-mediated survival mechanism. The data presented here suggest that growth factors
with the ability to activate the small GTPase Rac may stimulate
additional pathways to inhibit apoptosis. Rac is an effector of
multiple signaling pathways (38), any one of which may contribute to
the inhibition of apoptosis. Activated Rac promotes survival in BaF3
cells in a manner that is inhibited by the p38 kinase inhibitor
SB203580 (39). Rac can also activate the NADPH burst oxidase (40),
which, in turn, can activate the anti-apoptotic transcription factor
NF
(41, 42). This latter possibility suggests an additional
survival pathway dependent on new gene transcription. In this regard,
it is interesting to note that a novel anti-apoptotic signaling pathway
was recently described for the IGF I receptor that is sensitive to the
RNA polymerase II inhibitor
-amanitin (19). The identification of
Rac as a transitional element in these biological events should provide a valuable point of reference for the identification and ordering of
additional signaling intermediates that regulate cytoskeletal changes
and survival by the insulin receptor kinase.
| |
ACKNOWLEDGEMENTS |
|---|
We express our appreciation to A. Hall, D. Bar-Sagi, and G. Evan for reagents; to Genetics Institute (Cambridge, MA.) for the invaluable gift of recombinant human CSF-1; and to R. Cotter for preliminary experiments that led to these studies.
| |
FOOTNOTES |
|---|
* This work was supported in part by Grants RPG-96-134-03-TBE from the American Cancer Society, DK52809 from the National Institutes of Health, 99-24 from the Nebraska Department of Health and Human Services, and P30 CA36727 from the National Cancer Institute to the Eppley Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Supported by Training Grant CA09476 from the National Cancer Institute.
** To whom correspondence should be addressed: Eppley Cancer Institute, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805. Tel.: 402-559-8290; Fax: 402-559-4651; E-mail: rlewis@unmc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
IGF I, insulin-like
growth factor I;
IRS, insulin receptor substrate, CSF-1,
colony-stimulating factor-1;
CSF1R/IR, colony-stimulating factor-1
receptor/insulin receptor chimera;
CSF1R/IR
960, receptor chimera
containing a 12-amino acid deletion in the cytoplasmic juxtamembrane
region;
PI, phosphatidylinositol, GFP, green fluorescent protein, MAP,
mitogen-activated protein;
ERK, extracellular regulated kinase;
TRITC, tetramethylrhodamine B isothiocyanate.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | White, M. F., Livingston, J. N., Backer, J. M., Lauris, V., Ullrich, A., and Kahn, C. R. (1988) Cell 54, 641-649[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Maegawa, H.,
McClain, D. A.,
Friedenberg, G.,
Olefsky, J. M.,
Napier, M.,
Lipari, T.,
Dull, T. J.,
Lee, J.,
and Ullrich, A.
(1988)
J. Biol. Chem.
263,
8912-8917 |
| 3. |
Theis, R. S.,
Ullrich, A.,
and McClain, D. A.
(1989)
J. Biol. Chem.
264,
12820-12825 |
| 4. |
Yonezawa, K.,
Ando, A.,
Kaburagi, Y.,
Yamamoto-Honda, R.,
Kitamura, T.,
Hara, K.,
Nakafuku, M.,
Okabayashi, Y.,
Kadowaki, T.,
Kaziro, Y.,
and Kasuga, M.
(1994)
J. Biol. Chem.
269,
4634-4640 |
| 5. |
Chaika, O. V.,
Chaika, N.,
Volle, D. J.,
Wilden, P. A.,
Pirrucello, S. J.,
and Lewis, R. E.
(1997)
J. Biol. Chem.
272,
11968-11974 |
| 6. |
Boehm, J. E.,
Chaika, O. V.,
and Lewis, R. E.
(1998)
J. Biol. Chem.
273,
7169-7176 |
| 7. |
Chaika, O. V.,
Chaika, N.,
Volle, D. J.,
Hayashi, H.,
Ebina, Y.,
Wang, L. M.,
Pierce, J. H.,
and Lewis, R. E.
(1999)
J. Biol. Chem.
274,
12075-12080 |
| 8. | Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. (1994) EMBO J. 13, 3286-3295[Medline] [Order article via Infotrieve] |
| 9. | Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B. (1997) Biochim. Biophys. Acta Rev. Cancer 1332, F105-F126[Medline] [Order article via Infotrieve] |
| 10. | Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S., and Binoux, M. (1986) Anal. Biochem. 154, 138-143[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R. J.,
Cooper, G. M.,
Segal, R. A.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665 |
| 12. | Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H. A., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Kauffman-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. (1997) Nature 385, 544-548[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Shoelson, S. E.,
Chatterjee, S.,
Chaudhuri, M.,
and White, M. F.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
2027-2031 |
| 15. | Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X.-J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479[Medline] [Order article via Infotrieve] |
| 16. |
Myers, M. G., Jr.,
Backer, J. M.,
Sun, X. J.,
Shoelson, S.,
Hu, P.,
Schlessinger, J.,
Yoakim, M.,
Schaffhausen, B.,
and White, M. F.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10350-10354 |
| 17. |
Pear, W. S.,
Nolan, G. P,
Scott, M. L.,
and Baltimore, D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8392-8396 |
| 18. | Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. (1992) Cell 69, 119-128[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Kulik, G.,
and Weber, M. J.
(1998)
Mol. Cell. Biol.
18,
6711-6718 |
| 20. |
Joneson, T.,
Fulton, J. A.,
Volle, D. J.,
Chaika, O. V.,
Bar-Sagi, D.,
and Lewis, R. E.
(1998)
J. Biol. Chem.
273,
7743-7748 |
| 21. | Bockus, B. J., and Stiles, C. D. (1984) Exp. Cell Res. 153, 186-197[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y., Sakaue, H., Ando, A., Chavanieu, A., Calas, B., Grigorescu, F., Nishiyama, M., Waterfield, M. D., and Kasuga, M. (1994) EMBO J. 13, 2313-2321[Medline] [Order article via Infotrieve] |
| 23. | Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Han, J. W.,
Luby-Phelps, K.,
Das, B.,
Shu, X. D.,
Xia, Y.,
Mosteller, R. D.,
Krishna, U. M.,
Falck, J. R.,
White, M. A.,
and Broek, D.
(1998)
Science
279,
558-560 |
| 25. |
Nimnual, A. S.,
Yatsula, B. A.,
and Bar-Sagi, D.
(1998)
Science
279,
560-563 |
| 26. | Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Klippel, A., Kavanaugh, W. M., Pot, D., and Williams, L. T. (1997) Mol. Cell. Biol. 17, 338-344[Abstract] |
| 28. |
Franke, T. F.,
Kaplan, D. R.,
Cantley, L. C.,
and Toker, A.
(1997)
Science
275,
665-668 |
| 29. |
Frech, M.,
Andjelkovic, M.,
Ingley, E.,
Reddy, K. K.,
Falck, J. R.,
and Hemmings, B. A.
(1997)
J. Biol. Chem.
272,
8474-8481 |
| 30. | Backer, J. M., Schroeder, G. G., Cahill, D. A., Ullrich, A., Siddle, K., and White, M. F. (1991) Biochemistry 30, 6366-6372[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Gustafson, T. A., He, W., Craparo, A., Schaub, C. D., and O'Neill, T. J. (1995) Mol. Cell. Biol. 15, 2500-2508[Abstract] |
| 32. |
O'Neill, T. J.,
Craparo, A.,
and Gustafson, T. A.
(1994)
Mol. Cell. Biol.
14,
6433-6442 |
| 33. | Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. (1996) Science 271, 810-812[Abstract] |
| 34. | Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., and Downward, J. (1997) Cell 89, 457-467[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Cardone, M. H.,
Roy, N.,
Stennicke, H. R.,
Salvesen, G. S.,
Franke, T. F.,
Stanbridge, E.,
Frisch, S.,
and Reed, J. C.
(1998)
Science
282,
1318-1321 |
| 37. | Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Tapon, N., and Hall, A. (1997) Curr. Opin. Cell Biol. 9, 86-92[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Nishida, K., Kaziro, Y., and Satoh, T. (1999) Oncogene 18, 407-415[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Abo, A., Pick, E., Hall, A., Totty, N., Teahan, C. G., and Segal, A. W. (1991) Nature 353, 668-670[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Perona, R.,
Montaner, S.,
Saniger, L.,
Sanchez-Perez, I.,
Bravo, R.,
and Lacal, J. C.
(1997)
Genes Dev.
11,
463-475 |
| 42. | Sulciner, D. J., Irani, K., Yu, Z. X., Ferrans, V. J., Goldschmidt-Clermont, P., and Finkel, T. (1997) Mol. Cell. Biol. 16, 7115-7121[Abstract] |
This article has been cited by other articles:
![]() |
Q.-L. Fu, B. Hu, W. Wu, R. B. Pepinsky, S. Mi, and K.-F. So Blocking LINGO-1 Function Promotes Retinal Ganglion Cell Survival Following Ocular Hypertension and Optic Nerve Transection Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 975 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhang, Y. Zhang, and E. Shacter Caspase 3-Mediated Inactivation of Rac GTPases Promotes Drug-Induced Apoptosis in Human Lymphoma Cells Mol. Cell. Biol., August 15, 2003; 23(16): 5716 - 5725. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Otsuki, M. Tanaka, T. Kamo, C. Kitanaka, Y. Kuchino, and H. Sugimura Guanine Nucleotide Exchange Factor, Tiam1, Directly Binds to c-Myc and Interferes with c-Myc-mediated Apoptosis in Rat-1 Fibroblasts J. Biol. Chem., February 7, 2003; 278(7): 5132 - 5140. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Eichhorn, A. G. Kayali, L. Resor, D. A. Austin, D. W. Rose, and N. J. G. Webster PLC-{gamma}1 Enzyme Activity Is Required for Insulin-Induced DNA Synthesis Endocrinology, February 1, 2002; 143(2): 655 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qi, P. Juo, J. Masuda-Robens, M. J. Caloca, H. Zhou, N. Stone, M. G. Kazanietz, and M. M. Chou Caspase-mediated Cleavage of the TIAM1 Guanine Nucleotide Exchange Factor during Apoptosis Cell Growth Differ., December 1, 2001; 12(12): 603 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Linseman, T. Laessig, M. K. Meintzer, M. McClure, H. Barth, K. Aktories, and K. A. Heidenreich An Essential Role for Rac/Cdc42 GTPases in Cerebellar Granule Neuron Survival J. Biol. Chem., October 12, 2001; 276(42): 39123 - 39131. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Clerk, F. H. Pham, S. J. Fuller, E. Sahai, K. Aktories, R. Marais, C. Marshall, and P. H. Sugden Regulation of Mitogen-Activated Protein Kinases in Cardiac Myocytes through the Small G Protein Rac1 Mol. Cell. Biol., February 15, 2001; 21(4): 1173 - 1184. [Abstract] [Full Text] |
||||
![]() |
S. J. Coniglio, T.-S. Jou, and M. Symons Rac1 Protects Epithelial Cells against Anoikis J. Biol. Chem., July 20, 2001; 276(30): 28113 - 28120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Caruso, M. A. Maitan, G. Bifulco, C. Miele, G. Vigliotta, F. Oriente, P. Formisano, and F. Beguinot Activation and Mitochondrial Translocation of Protein Kinase Cdelta Are Necessary for Insulin Stimulation of Pyruvate Dehydrogenase Complex Activity in Muscle and Liver Cells J. Biol. Chem., November 21, 2001; 276(48): 45088 - 45097. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |